Form 4: Revolution Medicines Executive Sells Shares
Insider Transaction (Form 4)
Mark A Goldsmith, See Remarks and a Director of Revolution Medicines, Inc., sold 13,988 shares of common stock on September 16, 2026.
Summary
- Open-market sale: disposed of 213 Common Stock at $195.01 ($41,537) on September 16, 2026; holds 267,117 after (Direct).
- Open-market sale: disposed of 13,775 Common Stock at $199.30 ($2,745,402) on September 16, 2026; holds 253,342 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,786,938 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Mark A Goldsmith — Director, Officer (See Remarks)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-16 | Open-market sale | Common Stock | 213 | $195 | $41.5K | 267,117 |
| 2026-09-16 | Open-market sale | Common Stock | 13,775 | $199 | $2.7M | 253,342 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-16 | Open-market sale (213 shares) |
| 2026-09-16 | Open-market sale (13,775 shares) |
Keywords
insider transaction, Form 4, RVMD, Revolution Medicines, Inc., bearish, Mark A Goldsmith
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.